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Abstract
Genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs)
associated with trait diversity and disease susceptibility, yet the functional properties of many genetic
variants and their molecular interactions remains unclear. It has been hypothesized that SNPs in mi-
croRNA binding sites may disrupt gene regulation by microRNAs (miRNAs), short non-coding RNAs
that bind to mRNA and downregulate the target gene. While a number of studies have been conducted to
predict the location of SNPs in miRNA binding sites, to date there has been no comprehensive analysis
of how SNP variants may impact miRNA regulation of genes.
Here we investigate the functional properties of genetic variants and their effects on miRNA regula-
tion of gene expression in cancer. Our analysis is motivated by the hypothesis that distinct alleles may
cause differential binding (from miRNAs to mRNAs or from transcription factors to DNA) and change
the expression of genes. We previously identified pathways—systems of genes conferring specific cell
functions—that are dysregulated by miRNAs in cancer, by comparing miRNA–pathway associations be-
tween healthy and tumor tissue. We draw on these results as a starting point to assess whether SNPs in
genes on dysregulated pathways are responsible for miRNA dysregulation of individual genes in tumors.
Using an integrative analysis that incorporates miRNA expression, mRNA expression, and SNP geno-
type data, we identify SNPs that appear to influence the association between miRNAs and genes, which
we term “regulatory QTLs (regQTLs)”: loci whose alleles impact the regulation of genes by miRNAs.
We describe the method, apply it to analyze four cancer types (breast, liver, lung, prostate) using data
from The Cancer Genome Atlas (TCGA), and provide a tool to explore the findings.
1 Introduction
MicroRNAs (miRNAs) are small noncoding RNA molecules that modulate gene expression post-transcriptionally
by means of complementary base pairing with mRNA transcripts. Through recognition of short target mo-
tifs (6-8 bases long) on the target mRNA, miRNAs bind and down-regulate the expression of the targetted
gene. Regions flanking the “seed region” of the miRNA typically also bind the mRNA, creating a stronger
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annealing between the two RNA molecules. This results in the transcript being prevented from being trans-
lated into protein or degraded in the cell [1]. Because these molecular interactions are executed through base
pairing, they can be influenced by genomic variation; changes in genome sequence may influence binding
energy and the strength of annealing, or may even abrogate miRNA target sites entirely [2].
Polymorphisms constitute approximately 1% of the human genome and contribute to phenotypic diver-
sity and susceptibility to disease. As such, large-scale resources to annotate known single nucleotide poly-
morphisms (SNPs) have been constructed, including dbSNP [3] and the International Hapmap Project [4],
to describe all known patterns of genetic variation. Polymorphisms in miRNA and target site sequences
have been implicated in aberrant miRNA-mRNA interactions and have been associated with multiple can-
cers [5–7], suggesting a link bewteen genetic variation, miRNA regulation, and disease. Typically, dis-
coveries of prognostic SNPs come from genome-wide association studies (GWAS), which statistically link
variants with phenotypic traits. Recent GWAS studies have demonstrated that polymorphisms in miRNA
binding sites increase the risk of breast [8,9], bladder [10], and colon [11,12] cancers, among others. In
addition, several studies [2,5] have suggested that polymorphisms within miRNA regulatory networks affect
clinical outcomes and treatment responses.
In recent years, SNPs and their functional effects on miRNA regulation of genes have gained significant
interest due to observed genetic variation within miRNA networks, and several databases and computational
tools have been developed dedicated toward the study of polymorphic miRNA binding sites. These resources
include PolymiRTS [13] (a database which links polymorphisms with miRNAs and target sites, in addition
to diseases and biological pathways), Patrocles [14] (polymorphisms which are predicted to perturb miRNA-
gene regulation, including eQTLs and Copy Number Variations), and dbSMR [15] (SNPs around miRNA
target sites, genome-wide). These resources have improved the search for polymorphic binding sites and
their potential functional effects in the cell. Analogous resources exist to study variation within transcription
factor (TF) and TF binding sites [16].
GWAS arrays are not comprehensive, however, and often under-sample genomic variants within known
miRNA binding regions in the genome [17]. Additionally, while SNP variants may be predicted to af-
fect miRNA-gene regulation based on their genomic position, the magnitude of the effect is often unclear.
Hence, GWAS data alone is often insufficient to fully explore the relationship between genetic variation
and miRNA regulation. Recently, researchers have combined GWAS data with separate miRNA expression
data in head and neck squamous cell (HNSCC) carcinoma to assess variants genome-wide affecting miRNA
pathways in cancer [18]. There, the authors first conducted a GWAS to identify HSNCC-associated SNP
loci, cross-referenced them against putative miRNA:mRNA binding sites, and confirmed that those miRNAs
exhibited differential expression in the TCGA HSNCC data. To date, however, no attempts have been made
to directly integrate SNP, miRNA, and gene expression data from the same samples to identify SNPs that
disrupt miRNA–gene associations, and the functional effects of many polymorphisms and their molecular
interactions remain unknown.
To consider the functional effects of SNPs in miRNA networks, several criteria are required as outlined
in [19]. These criteria include independent association with the phenotype of interest, gene expression
within the tissue, allelic changes which result in differential binding between miRNA and target gene(s), and
resultant differential target gene expression. Concrete guidelines were suggested for future investigations to
combine genetic and functional evidence for polymorphisms in miRNA target sites and human disease [7].
Follow-up functional experiments were suggested, in order to strengthen evidence of differential regulation.
However, functional binding experiments are experimentally costly at scale, and are typically applied to
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specific systems of interest. As an alternative, several in silico tools have been developed to predict SNP
effects on miRNA-gene interactions [20,21]. However, these tools often fail to predict interactions that have
been been observed in experiment [22].
To date, the functional effects of polymorphisms are typically explored by integrating GWAS and gene
expression data find expression Quantitative Trait Loci (eQTLs): SNP variants that result in altered gene
expression. Many eQTLs have been identified, including several associated with cancer. Recent integrative
analyses using data from The Cancer Genome Atlas (TCGA) identified eQTLs in Breast Cancer [23] and
Glioblastoma Multiforme [24,25]. In fact, combinations of GWAS data with eQTL studies have found
alleles that affect gene expression and complex traits genome-wide [26]. However, these analyses do not
necessarily reveal the functional effects of polymorphisms on molecular-molecular interactions, particularly
with respect to differential binding, as in miRNA-gene or TF-gene interactions.
Data from the TCGA project provides an ideal opportunity to investigate the function of genetic vairants
by integrating SNP, gene expression, and miRNA expression from the same set of samples. Here, we
propose a method to integrate these data to reveal genetic variants that show evidence of impacting miRNA-
gene regulatory relationships. Motivated by the observation that integrative omics analyses provide more
insight than single-platform approaches [27,28], we perform an integrative omics analysis that searches for
polymorphisms that modulate co-expression between miRNAs and their putative gene targets, which we
term “regulatory QTLs (regQTLs)”: loci whose alleles impact the regulation of genes by miRNAs. Using
mRNA expression, miRNA expression, and genotype data taken from tumor tissues, our method applies a
regression model to assess whether disparate alleles present at a genomic variant modulate the miRNA-gene
co-regulatory relationship. By comparing miRNA expression and gene expression across genotypes, we can
identify regQTLs, or polymorphic sites which may alter molecular interactions and may be implicated in
tumorigenesis. Importantly, by using miRNA and gene expression data, we avoid the inaccuracies associated
with miRNA binding prediction algorithms, and are able to directly estimate the magnitude of the impact
that the SNP has on the regulatory relationship.
Below, we present the method and apply it to TCGA data from four separate cancer types (breast, lung,
liver, prostate). We report findings of gene variants that modulate miRNA regulation of gene expression in
each of the cancer types studied. Interestingly, some of the flagged miRNAs and genes have been previously
implicated in tumorigenic processes in the literature, and SNPs demonstrate functional changes to gene
regulation. These results may have implications for future research in genomic regulation in tumors.
2 Methods
We seek to identify regQTLs, genomic variants that influence miRNA regulation of gene expression, by
integrating genomic and expression data from TCGA data. Specifically, we test whether different alleles at
a SNP locus within a given gene alters how a miRNA modulates the expression of that gene across TCGA
tumor samples. regQTLs may then provide context to gene regulation in cancer, due to genetic diversity or
genetic alterations.
Previously [29], we had identified sets of genes, or pathways, whose overall activity appeared to be
dysregulated by miRNAs in tumors in comparison to healthy tissue in four separate cancer types (breast,
lung, liver, prostate). Our method first obtained an expression-based summary of pathway activity using
Isomap [30], and then searched for differential miRNA correlations with the pathway summary across phe-
notypes, to find miRNA-pathway relationships at the systems level that were disrupted in cancer. Using data
from The Cancer Genome Atlas (TCGA), we tested ∼105 unique miRNA-pathway relationships, many of
which were significantly dyregulated.
Here we focus on those dysregulated miRNA-pathway pairs, and explore whether SNPs on the pathways
are responsible for miRNA dysregulation of individual genes within that pathway. In other words, for each
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miRNA-pathway pair, we explore the co-expression patterns between the miRNA and the genes on the
pathway, modulated by each of the polymorphisms located on the gene. By restricting our focus to genes
in dysregulated miRNA-pathway pairs, we can ensure that the polymorphisms under consideration reside
within perturbed systems in cancer. In addition, this restriction effectively reduces the dimensionality of
our genome-wide analysis. We apply our methodology to TCGA data to explore all miRNA-mRNA-SNP
combinations from miRNA-gene pairs where the gene was part of a dysregulated miRNA-pathway system,
amounting to ∼106 models per cancer type (breast, lung, liver, prostate). For each cancer, we report
regQTLs which appear to modulate the co-regulatory miRNA-gene relationship in tumors and may therefore
contribute to tumorigenesis.
2.1 Analytical approach
We consider all miRNA-gene pairs from dysregulated pathways that exhibited a differential association
p < 0.01 in our prior analysis [29]. We systematically probe all unique miRNA-mRNA-SNP trios across all
tumor samples in a cancer cohort. For each unique trio, we compute a multiple linear regression to model the
expression of a gene as a response as a function of the miRNA expression, the SNP allele (treated as a cate-
gorical variable), and the interaction between them. Specifically, for a SNP with genotypes {AA,Aa, aa},
we fit
Y = β0 + β1XmiR + β21(SNP=Aa) + β31(SNP=aa)+
β41(SNP=Aa)XmiR + β51(SNP=aa)XmiR + ε ,
(1)
where Y represents the expression level of the gene of interest, XmiR is the expression level of the miRNA,
and 1(·) is an indicator function for the SNP genotype. In this model, the coefficient β1 quantifies the re-
lationship between the miRNA and gene expression for the reference genotype AA; the coefficients β2, β3
quantify how the allele affects overall expression of the gene (i.e., as an eQTL); and the interaction coeffi-
cients β4, β5 quantify how the variant alleles at the SNP of interest modulate the miRNA-mRNA relation-
ship. SNPs with strong interaction effects are inferred to be potential regQTLs.
SNPs are treated as categorical variables in our model to capture any dominant, recessive, or additive
effects that individual alleles may confer on miRNA-gene interactions. Because any single copy of an allele
may create, strengthen, weaken, or abrogate miRNA-gene binding, we seek to capture all possible SNP
effects and their cross-comparisons. For instance, an allele that creates strong miRNA-gene binding may
only need to be present in one copy to show an effect, such that the salient difference is observed between
having no copy of the variant allele and having one or two copies (with no difference between one and two).
Alternatively, an allele that abrogates miRNA-gene binding may be seen to have a strong effect for those
with homozygous copies, but a much weaker effect for heterozygous individuals. As such, we explore all
allelic effects on miRNA-gene binding.
To assess the statistical significance of the interaction effect, we apply ANOVA Type III sums of squares
(Yates’s weighted squares of means) to compare the full model to that without the interaction terms. A
significant F statistic for the interactions suggests that at least one of the variant SNP alleles substantially
alters the relationship between the miRNA and the mRNA, on top of any eQTL-like effects. p-values for
all interactions are then FDR-adjusted [31] for the large number of miRNA-mRNA-SNP trios probed in the
dataset. (We choose this Benjamini-Hochberg FDR adjustment because we expect that models with common
miRNAs or genes are not strictly independent, and this procedure has been show to provide control of the
FDR under dependency [32].) The steps of the method are summarized in Table 1. Figure 1 illustrates the
intuition underlying the method.
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Table 1: Procedure for assessing genomic variants modulating miRNA-gene interactions
Method for finding regQTLs
1. Select dysregulated miRNA-pathway pairs (p < 0.01) following the method from [29] (Figure 1a).
2. For each miRNA-pathway pair, find all genes on the pathway and all assayed SNPs on each gene to construct all
unique miRNA-mRNA-SNP trios (Figure 1b, top).
3. For each trio in Step 2, fit Equation 1 and apply ANOVA to assess statistical significance of the interaction terms
(Figure 1b, bottom).
4. FDR-adjust the resulting ANOVA p-values.
5. Report highly significant miRNA-mRNA-SNP trios as potential regQTLs.
2.2 Application to TCGA data
As a proof of concept, we applied this method systematically to tumor samples with combined miRNA
expression, gene expression, and SNP genotype data from TCGA.
Data TCGA data were downloaded for BRCA (breast), LIHC (liver), LUSC (lung), and PRAD (prostate)
cancers. Tumor samples (TCGA sample type “01”) measured across mRNA IlluminaHiSeq RNASeqV2
(Level 3), miRNA IlluminaHiSeq miRNASeq (Level 3), and Affymetrix SNP6.0 platforms were used for
the analysis, amounting to 699 total tumor samples in breast, 345 in liver, 341 in lung, and 481 in prostate
cancer.
Data preprocessing and filtration Briefly, mRNA data were converted to TPM and log2 transformed,
and miRNA data were log2 transformed (both with small offsets for the log transformation). In addition,
genes and miRNAs were removed from consideration that had very low expression across most samples
in the set (defined as genes with median expression < 10−9 before TPM conversion and miRNAs having
expression ≤ 1 for more than half of the samples in the set before log transformation).
SNPs were filtered out that had a low Birdseed confidence threshold (0.05) for genotype calls in the
TCGA pipeline. We used two additional filtration criteria to remove SNPs: a) those having minor allele
frequencies (MAF) less than 1% and b) those having genotype frequencies less than 5% across all samples
in a cancer dataset. These criteria were imposed to ensure that limited sampling of rare alleles and genotypes
would not skew the regression results.
Before applying the regression models, individual samples within a miRNA-mRNA-SNP trio having no
appreciable miRNA expression were removed from consideration, since they are not biologically of interest.
Additionally, samples having a large Cook’s Distance (D > 1) were removed from the regressions and the
regressions were recomputed to limit the influence of outliers on the resulting models.
3 Results
We begin by presenting qq-plots of the regQTL p-values across all miRNA-mRNA-SNP trios in TCGA
breast, liver, lung, and prostate cancer samples (Figure 2). It can be seen here that several trios in each study
achieve extremely small p-values of p ≤ 10−9, indicating regQTLs that achieve genome–wide significance
(even using the conservative Bonferroni correction).
It may also be observed that the distribution of regQTL p-values exhibit systematic deviations from
the expected uniform distribution of p values under the null, with many more significant observations than
expected by chance for independent tests (as demonstrated by the trend away from the red diagonal lines).
Such systematic deviations suggest that the trios are not strictly independent of one another; in classical
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Figure 1: Illustration of the procedure to identify regQTLs: SNPs that modify the miRNA-mRNA relation-
ship in dysregulated pathways. The method integrates gene expression, miRNA expression, and SNP data.
(a) To aid mechanistic interpretability and reduce the search space, we first identify miRNA–pathway pairs
that exhibit significant evidence of differential regulation following [29]. (b) Within each miRNA–identified
pathway pair, we construct all miRNA-mRNA-SNP trios for each gene in the pathway (top), and system-
atically test whether the SNP modifies the expression relationship between the miRNA and the mRNA
(bottom). Table 1 details the method.
GWAS, this is often attributable to population substructure driving the results. Here, however, some depen-
dency amongst the tests is expected. Because we consider all known SNPs on each gene, many of the SNPs
will be in linkage disequilibrium (LD) owing to their genomic proximity and will be correlated. Variants in
LD have been observed in blocks ranging from tens of Kbs to greater 100 Kbp [33], which may be larger
than the size of a gene. In addition, because we consider genes within pathways, the expression of the genes
may be correlated due to similar co-regulatory mechanisms or cooperate effects within a network. Popu-
lation substructure may also be a factor in data drawn from diverse genetic populations. However, TCGA
heavily samples from European ancestry; we tested for substructure by applying PCA to genotype data,
and found that most of the samples comprised a single tight cluster in the first two principal components,
as shown in Supplementary Figures S1–S4. Because we expect the tests to exhibit some dependency, we
perform multiple hypothesis adjustment using FDR [31,32], rather than using the Bonferroni adjustment,
which assumes independent tests and can be excessively conservative otherwise.
3.1 Breast cancer
In breast cancer, ∼1.28× 107 unique gene-miRNA-SNP trios, drawn from 25,850 miRNA×pathway pairs,
were analyzed and shown in Figure 3. Several chromosomes contain clusters of significant observations, as
demonstrated by upward spikes within specific genomic regions. These clusters are composed of SNPs at
different loci in close proximity with one another whose alleles are in LD. SNPs in LD are influenced by
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Figure 2: Quantile-quantile plots of the observed p-values for the gene-miRNA-SNP ANOVA interaction
tests versus their expected p-value distributions (the uniform distribution), tested in each cancer type. There
were approximately 1.29×107 unique interactions tested in breast, 3.65×106 in liver, 8.03×106 in lung, and
4.32 × 106 in prostate cancer. A horizontal blue line indicates the threshold for genome–wide significance
under the conservative Bonferroni adjustment.
rates of recombination and mutation and reflect evolutionary history. Because of their genomic proximity,
SNPs in linkage often lie within the same genes, such that multiple variants in a gene may wield similar
biological effects on miRNA regulation, as demonstrated in Figure 3.
Figure 3: Breast cancer manhattan plot. All gene-miRNA-SNP interaction p-values mapped to the location
of the SNP in the genome. Observations are colored by chromosome. p-values are adjusted for the False
Discovery Rate.
This is evident when we observe regQTLs, all trios that were flagged as significant after FDR-adjustment
(FDR ≤ 0.1), of which relatively few achieve significance (3369). Among the flagged regQTLs, some
miRNA-gene pairs are represented frequently, with multiple SNPs in the gene appearing to modulate the
miRNA-gene relationship. Table 2 lists the miRNA-gene pairs with the largest number of significant
regQTLs achieving significance with FDR ≤ 0.1. (Note that Table 2 is not an exhaustive list but rather
displays the highest number of modulating SNPs within miRNA-gene interactions at a given FDR.)
It is notable that in several pairs in Table 2, the miRNA is not predicted to target the gene based off
sequence matching from microRNA.org [34]. This may be due to several factors. First, not all miRNA-
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Table 2: miRNA-gene pairs containing the most number of gene variants significantly modulating their
interactions in breast cancer. “SNPs” indicates the number of associated SNPs on the gene found to signif-
icantly modulate (at pFDR ≤ 0.1) the miRNA-gene interaction, out of the total number of known SNPs on
the gene. pMIN indicates the most significant interaction p-value after FDR-correction. “chr” indicates the
chromosome where the SNP is located.“target” indicates whether the miRNA is predicted to target the gene
based off sequence matching from microRNA.org.
SNPs
miRNA gene associated total pMIN chr target
hsa-mir-221 FGF14 14 334 7.57E-04 13 TRUE
hsa-mir-642a MTOR 14 38 3.97E-03 1 FALSE
hsa-mir-141 FOXO1 13 44 2.16E-02 13 TRUE
hsa-mir-642a NUP210 13 173 4.93E-02 3 FALSE
hsa-mir-154 ELMO1 10 313 8.67E-04 7 FALSE
hsa-mir-200c FOXO1 10 44 4.13E-02 13 TRUE
hsa-mir-200c GALNT10 10 123 1.04E-02 5 TRUE
hsa-mir-3200 GSPT2 9 15 4.46E-02 X FALSE
hsa-mir-125b-2 LRRC4C 9 479 4.85E-03 11 FALSE
hsa-mir-141 EDA2R 8 37 6.66E-02 X TRUE
hsa-mir-222 FGF14 8 334 3.07E-04 13 TRUE
hsa-mir-141 SFRP2 8 64 1.59E-02 4 FALSE
hsa-mir-190b TUSC3 8 235 3.07E-04 8 TRUE
hsa-mir-452 TUSC3 8 235 1.50E-02 8 FALSE
hsa-mir-190b NUP210 7 173 1.77E-02 3 FALSE
gene interactions are known, and some interactions have been observed in experiment that have not been
predicted through sequence matching [22]. Because these miRNA-gene pairs are modulated by many gene
variants, these may represent novel biological interactions between miRNAs and genes that have yet to be
documented and that are sensitive to biological variation. Another possibility is that these miRNAs and
genes may not interact directly, but may be indirectly connected through second-order effects—for instance,
one can envision a miRNA target interacting with the gene listed in the pair in Table 2. This may lead to an
apparent association with the miRNA, although it is mediated through another gene.
Examples of significant trios are shown in Figure 4. For instance, in the left panel, samples with the ho-
mozygous minor (AA) genotype exhibit a strong negative dependence between hsa-mir-190b and TUSC3,
whereas the heterozygous (AC) and homozygous major (CC) genotypes exhibit weaker and no dependen-
cies. One explanation may be that samples having both A alleles confer strong binding between hsa-mir-
190b and TUSC3, whereas the introduction of the C allele confers weaker (AC) or no binding (CC) at all.
hsa-mir-190b is predicted to target TUSC3 by sequence matching, and both the miRNA and gene are im-
plicated in cancer in the literature. TUSC3 is a tumor suppressor whose loss or decreased expression is
associated with the proliferation of several cancer types [35–37] and is markedly under-expressed in breast
cancer cells [38]. hsa-mir-190b has recently been found to be the most upregulated miRNA in ERα breast
cancers relative to ERα negative breast cancers [39], and is part of the regulatory network that activates
p53 [40]. Likewise, in the middle panel, hsa-mir-221 is predicted to target FGF14 and exhibits regulatory
differences across genotypes. In this case, the homozygous minor (AA) appears to confer a loss of reg-
ulation, whereas the introduction of the G allele in the heterozygous (AG) and homozygous major (GG)
genotypes, confers negative regulation and perhaps strong binding. hsa-mir-221/222 has previously been
associated with a basal-like phenotype and the epithelial to mesenchymal transition in breast cancer [41].
Although FGF14 in particular is not implicated in cancer, aberrant signaling of other Fibroblast Growth
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Figure 4: Examples of breast cancer gene-miRNA-SNP trios with significant regulatory differences across
genotypes. All trio interactions pFDR < 0.005.
Factors are widely found in the pathogenesis of cancer [42].
In the right panel, the anomalous genotype, homozygous major (GG), is associate with a strong positive
dependence between hsa-mir-642a and MTOR, in contrast to the other panels. The positive dependence,
coupled with the fact that hsa-mir-642a is not predicted to target MTOR, may be evidence that our method is
flagging second-order effects driven by genomic variation. Furthermore, hsa-mir-642, the miRNA family of
hsa-mir-642a, contains many genes that interact with MTOR, including many MAP kinases and TP53 that
are implicated in breast cancer in the literature. The examples shown in Figure 4 are illustrative of the types
of regulatory interactions affected by genomic variation we observe within breast cancer.
3.2 Liver cancer
A total of 3.65 × 106 gene-miRNA-SNP unique trios, drawn from 7371 miRNA×pathway pairs, were
mapped to their loci in the genome in Figure 5 for liver cancer. Although fewer trios achieve significance in
comparison to breast cancer (76 regQTLs with FDR ≤ 0.1), we again observe the associated SNPs to be
clustered due to linkage. As above, Table 3 presents the miRNA-gene pairs that have the greatest number
of regQTLs. The top gene, POLR3B, contains 6 SNPs that each modulate its regulation by hsa-mir-182,
depending on genotype. We illustrate one such example in Figure 6 (left plot), in which the anomalous
genotype (GG) for rs11112983 downregulates expression of POLR3B by hsa-mir-182, in comparison to the
others. POLR3B is subunit B (the second largest) of RNA polymerase III, which is the polymerase that
synthesizes transfer and small ribosomal RNAs. Increased RNA polymerase III output is widely implicated
in cancer [43]. Recently, a novel truncated version of POLR3B called INMAP has been observed to re-
press AP-1 and p53 activity and is upregulated in several cancer cell lines [44]. hsa-mir-182 is significantly
upregulated in hepatocellular carcinoma and has been found to promote proliferation and invasion by down-
regulating tumor suppressor EFNA5 [45] and promote metastasis by downregulating metastasis suppressor
1 [46]. While hsa-mir-182 itself isn’t predicted to target POLR3B, it is predicted to target other subunits on
RNA polymerase III, and therefore may exert second-order regulatory effects with POLR3B.
Another example of noteworthy genotype-dependent interactions we detect is shown in Figure 6 (right
plot). Not only is GSTM1 differentially regulated by hsa-mir-99a at rs2071487 depending on genotype, but
also GSTM1 exhibits initial genotype-dependent gene expression differences typical of a strong eQTL. In
this case, alleles appear to have the power to determine both expression and modulation of gene regula-
tion. GSTM1 is part of the GST-superfamily that detoxifies electrophilic compounds by conjugation with
glutathione, and is involved in processing carcinogens, drugs, and toxins. GSMT1 is highly polymorphic,
affecting toxicity and drug efficacy across individuals, and in particular, null mutations are associated with
an increase in susceptibility to lung, bladder, and colon cancers [47]. hsa-mir-99a inhibits hepatocellular
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carcinoma growth [48] and its dysregulation is an early marker of tumor progression [49]. While hsa-mir-
99a is not predicted to target GSTM1, it is predicted to target GSTM3 and GSTM5, other GST-superfamily
µ enzymes.
Figure 5: Liver cancer manhattan plot of regQTL −log10FDR values.
Table 3: miRNA-gene pairs with the greatest number of significant regQTLs (at pFDR ≤ 0.1) in liver cancer.
SNPs
miRNA gene associated total pMIN chr target
hsa-mir-182 POLR3B 6 34 9.22E-03 12 FALSE
hsa-mir-183 POLR3B 6 34 1.28E-02 12 FALSE
hsa-mir-107 NFYC 3 21 1.28E-02 1 TRUE
hsa-mir-125b-1 STS 3 212 1.18E-02 X TRUE
hsa-mir-122 ATP2B2 2 237 8.21E-03 3 TRUE
hsa-mir-655 CACNA1C 2 301 5.19E-02 12 TRUE
hsa-mir-215 DRD1 2 84 5.87E-02 5 FALSE
hsa-mir-139 GLDC 2 51 5.87E-02 9 FALSE
hsa-mir-203 PLCE1 2 118 3.32E-02 10 FALSE
hsa-mir-766 THOP1 2 3 6.74E-02 19 TRUE
hsa-mir-34c UGT1A6 2 43 5.01E-02 2 FALSE
3.3 Lung cancer
A total of 8.03 × 106 unique gene-miRNA-SNP trios, drawn from from 14433 miRNA×pathway pairs
in lung cance were mapped to their loci in the genome in Figure 7. Among the clusters of correlated
observations that spike in Figure 7, several miRNA-gene pairs are represented frequently and tabulated in
Table 4. MAOA, POLA1, and CTNNA2 on Chromosomes X and 2 collectively make up the bulk of the genes
containing SNPs modulating their observations in LD with each other.
In Figure 8 (left plot), one of the SNPs (rs5944699) modulating POLA1 and hsa-mir-337 is shown. All
three genotypes exhibit disparate regulation on the gene. Interestingly, the heterozygous genotype (AG)
demonstrates a negative regulatory effect rather than the homozygous genotypes. POLA1 is the catalytic
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Figure 6: Examples of liver cancer gene-miRNA-SNP trios with significant regulatory differences across
genotypes. All trio interactions pFDR < 0.005.
subunit of DNA Polymerase Alpha 1. hsa-mir-337 regulates the proliferation of several cancer types, in-
cluding pancreatic and gastric cancers.
Yet another example of anomalous regulation we detect is shown in Figure 8 (right plot). Here the CC
genotype for rs9372316 exhibits a strong positive correlation between hsa-mir-1247 and FYN, in contrast
to the other genotypes, which exhibit no appreciable correlation. hsa-mir-1247 is not predicted to target
FYN, providing additional evidence that we may be detecting secondary effects of allele-specific differences
on miRNA regulation of genes. hsa-mir-1247 is predicted to target several genes that interact with FYN,
including TNFRSF10B (tumor necrosis factor receptor) and CBL (proto-oncogene), that are implicated in
tumorigenic processes. FYN itself is a proto-oncogene of the Src family normally associated with T-cell
signaling, cell development and growth. FYN is upregulated in several cancer types including breast and
prostate cancers [50] and is associated with metastatic potential.
We note that in Table 4, CTNNA2 appears frequently with several miRNAs, often with the same SNPs.
Because the anomalous SNPs in CTNNA2 have relatively low representation among the cohort, it is difficult
to attribute confidence to their regulatory effect. That is, genotype frequencies for the homozygous minor
alleles (MAF: 28%–41%) may be undersampled for these SNPs (range: 9.9%–16.1%). Another note is that
CTNNA2 has low gene expression in lung tumor samples (< 0.1 TPM for∼ 92% of the samples). This may
subject it to biological fluctuations, due to noise and excluded samples, which may influence results.
3.4 Prostate cancer
A total of 4.3 × 106 unique gene-miRNA-SNP trios, drawn from 8673 miRNA×pathway pairs in prostate
cancer were mapped to their loci in the genome in Figure 9. The scale in Figure 9 is lower than the manhattan
plots in the other cancer types, with the most significant interaction p ∼ 0.0067. Nevertheless, we do
observe pairs containing many SNPs modulating their interactions in Table 5. In addition, many of these
miRNA-gene pairs are predicted to interact biologically based on sequence matching.
A few examples of trios we find in prostate cancer are shown in Figure 10. In the left plot, hsa-mir-
30a is predicted to target FBXW7, and shows a sharp negative regulatory dependence for the CC genotype,
whereas the other genotypes exhibit no appreciable miRNA-gene regulation. hsa-mir-30a and FBXW7 are
11
Figure 7: Lung cancer manhattan plot of regQTL −log10FDR values.
among the most frequently flagged pairs we find in prostate cancer. hsa-mir-30a is a tumor suppressor
that inhibits EMT genes that is typically down-regulated by oncogenic signals in prostate cancer like EGF,
particularly in metastasis [51]. FBXW7, an F-box protein, mediates ubiquitination and proteasomal degra-
dation of target proteins. Its down-expression, loss, and frequent mutation is shown in multiple cancer
types, including ovarian, breast, melanoma, colon, and others. In the right plot, the CC genotype exhibits
strong negative regulation between hsa-mir-1307 and ROBO1, whereas the other genotypes exhibit weaker
dependencies. hsa-mir-1307 is predicted to target ROBO1, and promotes proliferation in prostate cancer
by targeting FOXO3A [52]. ROBO1 itself is part of the immonoglobulin gene superfamily and is an axon
guidance receptor gene previously implicated in dyslexia.
3.5 Tool for interactive exploration of complete results
We have presented only a few examples of gene-miRNA-SNP trios tested in the cancer types shown above.
In order to enable researchers to explore other trios, we have produced an open source R Shiny application,
called mirApp, that can be used to investigate other trios in the analyzed datasets. The user is asked to choose
the cancer type (breast, liver, lung, or prostate) and input a specific miRNA of interest. The Shiny app then
produces a miRNA-specific manhattan plot of all significant regQTLs within the cancer type (pFDR ≤ 0.1).
This manhattan plot is interactive, such that when the user clicks on an individual regQTL point, the app
produces its trio interaction plot, similar to those in Figure 4. This tool can be downloaded freely from
https://github.com/gawilk/mirApp.
In addition, code to carry out the analysis (to reproduce these results or apply them to other SNP/miRNA/mRNA
datasets) can be obtained from https://github.com/gawilk/miRNA-SNP.
4 Discussion
We have described a novel integrative method that combines genomic and expression data to elucidate
the effects that genomic variants exert on miRNA regulation of genes in cancer. This integrative analysis
combines miRNA expression, mRNA expression, and genotype data from tumor tissue to find polymor-
phisms that modulate co-expression patterns between miRNAs and their putative gene targets, which we
term regQTLs. This analysis continues our previous work that identified miRNAs and entire pathways
12
Table 4: miRNA-gene pairs with the greatest number of significant regQTLs (at pFDR ≤ 0.1) in lung cancer.
SNPs
miRNA gene associated total pMIN chr target
hsa-mir-766 MAOA 10 91 1.82E-02 X TRUE
hsa-mir-337 POLA1 8 61 6.13E-03 X TRUE
hsa-mir-200b CTNNA3 7 654 3.44E-02 10 FALSE
hsa-mir-127 CTNNA2 6 732 1.76E-03 2 FALSE
hsa-mir-134 CTNNA2 6 732 1.76E-03 2 FALSE
hsa-mir-154 CTNNA2 6 732 8.51E-03 2 TRUE
hsa-mir-369 CTNNA2 6 732 4.27E-03 2 TRUE
hsa-mir-379 CTNNA2 6 732 6.68E-03 2 FALSE
hsa-mir-409 CTNNA2 6 732 1.76E-03 2 TRUE
hsa-mir-493 CTNNA2 6 732 8.51E-03 2 FALSE
hsa-mir-496 CTNNA2 6 732 8.51E-03 2 FALSE
hsa-mir-758 CTNNA2 6 732 1.65E-02 2 FALSE
hsa-mir-185 ADH4 5 16 4.57E-02 4 TRUE
hsa-mir-382 CTNNA2 5 732 3.44E-02 2 FALSE
hsa-mir-205 EGFR 5 125 3.23E-02 7 TRUE
whose co-regulation was found to be disrupted in tumors. Here, we hone in on previously identified dys-
regulated pathways, and determine whether polymorphisms present within pathway genes may contribute
to individual gene dysregulation.
This work is in the spirit of other integrative omics analyses to yield insights into gene expression
regulatory mechanisms. Its main novelty is to take into account genomic variation and apply it on a genome-
wide scale. Other integrative analyses of omics platforms have been applied to yield discoveries on gene
expression regulation mechanisms. Pipelines such as CrossHub [53] take into account miRNA and TF
relationships as well as methylation evidence, through TCGA and ENCODE ChIP-Seq binding evidence, to
describe regulation of gene expression. RACER [54] uses regression analysis to predict gene expression as a
function of genetic and epigenetic factors including copy number variation, miRNAs, DNA methylation, and
TF evidence combined from TCGA and ENCODE to study Acute Myeloid Leukemia. Another study [55]
combined similar input variables in a linear fashion to model mRNA expression changes in glioblastoma
tumor samples, and was able to identify activities that were predictive of subtypes and survival. These
studies have identified some relationships between expression regulators and genes and focused on mostly
single cancer types. Jacobsen and colleagues [56] used a statistical approach to model the recurrence of
miRNA-mRNA expression in tumor samples across multiple cancer types, induced by changes in DNA
copy number and promoter methylation. However, none of these studies have taken into account genomic
variation to address their effect on gene regulation.
In contrast, our method incorporates genomic variation to identify regQTLs. Our method is fully data
driven, integrating sample specific expression and genomic data to find allele-specific regulatory effects. By
applying multiple linear regression models using all three omics features, we can assess which SNPs differ-
entially affect miRNA regulation of genes. The use of linear models and ANOVA allow for relatively easy
assessment of statistical interactions. Because we focus on genes within pathways found to be co-regulated
with miRNAs which are disrupted in cancer, our approach may help find genomic variants that contribute
to tumorigenesis. We emphasize that the application to dysregulated pathways permits the identification of
regQTLs with potentially local and system effects, and significantly reduces the search space of mechanisms
under consideration in the genome.
We apply this analysis to breast, liver, lung, and prostate cancers, and within each cancer type, test
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Figure 8: Examples of lung cancer gene-miRNA-SNP trio with a significant regulatory difference across
genotypes. All trio interactions pFDR < 0.015.
millions of possible models (genes regulated by miRNAs modulated by SNPs, or “trios”). We find poly-
morphisms systematically affecting miRNA-gene regulation, with many more statistically significant effects
than expected by chance. This supports the notion that cancer contains significant perturbations to the entire
genome. Among the flagged trios with high significance, many miRNAs and genes are often implicated in
tumorigenic processes in the literature. These include tumor suppressor genes, genes in the the p53 net-
work, genes within signaling pathways, and miRNAs whose aberrant expression or aberrant targeting has
been documented in multiple cancer types. In addition, we find several genes each containing many individ-
ual variants differentially modulating miRNA regulation. These genes, and the genomic regions surrounding
them, may indicate hotspots of tumorigenic interest for future research.
Due to the extensive nature of the study, an R Shiny app has been developed to fully explore all regQTLs
and visualize their effects. Users can utilize the app interactively to observe regQTL significance genome-
wide by cancer type, and plot individual miRNA-gene interactions modulated by them. This utility allows
for complete exploration of our integrative analysis of TCGA data.
We note that the our results are somewhat limited by the input data. Currently, TCGA is the largest
known resource of cancer omics data, with samples assayed across both expression and genotype data.
However, individuals of European ancestry are highly overrepresented. Having comparable datasets in
diverse populations would strengthen the results of this study. In addition, our method only considers genes
and SNPs which lie on annotated pathways; genes and SNPs that are currently unannotated on biological
pathways, and therefore unconsidered in our model, may be of tumorigenic importance. Finally, our search
for regQTLs is highly flexible; we do not restrict miRNA-gene relationships to those already corroborated
with biophysical evidence, and, in addition, do not restrict genomic variants to those within putative miRNA
binding regions. These criteria have been set to allow for novel discoveries, since computational miRNA-
gene binding rules have been observed to deviate from experiment. However, we may also identify second-
order effects of miRNA regulation modulated by genotype (or possibly spurious relationships) that would
require functional experiments to elucidate. Nevertheless, we do find significant relationships in which the
genes and miRNAs are implicated in cancers in the literature.
Our model is relatively simple and can be efficiently applied to any combined miRNA/mRNA/SNP
dataset of interest to reveal the effects of a single regulatory SNP. We envision that future work could apply
14
Figure 9: Prostate cancer manhattan plot of regQTL −log10FDR values.
and extend our approach in several ways. For instance, it is conceivable that multiple SNPs in combination
will influence miRNA regulation of a gene, and that genomic variation may affect other layers of gene
regulation (e.g., but influencing transcription factor binding). Future extensions of this method could include
integrating TF binding sites or epigenetic factors in the analysis regQTLs. Given specific regQTLs identified
in this study, other avenues could include validating their differential regulation by experimental means,
or estimating their strength in silico. Perhaps the most exciting future application would be to inform
personalized medicine in the context of miRNA therapeutics [57–59]; for instance, the results shown in
Figure 4 suggest that targetting mir-190b could influence the expression of the tumor suppressor TUSC3,
but only amongst homozygous AA individuals at regQTL rs13253051.
Finally, we note that our method for identifying regQTLs can be easily applied to other diseases and
experimental modalities (such as TFs) to determine the functional impact of specific loci. A genome-wide
analysis of functional regulatory effects can help identify polymorphisms and mutations that contribute to
disease.
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Table 5: miRNA-gene pairs with the greatest number of significant regQTLs (at pFDR ≤ 0.1) in prostate
cancer.
SNPs
miRNA gene associated total pMIN chr target
hsa-mir-26a-2 CNTN1 14 135 6.68E-03 12 TRUE
hsa-mir-15b PARK2 6 636 1.96E-02 6 TRUE
hsa-mir-30a FBXW7 5 33 1.12E-02 4 TRUE
hsa-mir-1266 PDE4D 5 534 7.17E-02 5 TRUE
hsa-mir-143 EFNA5 4 247 2.54E-02 5 FALSE
hsa-mir-200c FBXW7 4 33 5.99E-02 4 TRUE
hsa-mir-330 NEGR1 4 241 6.93E-02 1 TRUE
hsa-mir-421 WBSCR17 4 336 1.96E-02 7 FALSE
hsa-mir-130b AKR1C3 3 42 3.86E-02 10 TRUE
hsa-mir-331 CACNA2D4 3 53 5.99E-02 12 TRUE
hsa-mir-766 CACNA2D4 3 53 6.11E-02 12 TRUE
hsa-mir-330 MASP1 3 55 1.96E-02 3 TRUE
hsa-mir-190 NPR2 3 4 7.38E-02 9 FALSE
hsa-mir-361 NTN4 3 42 2.20E-02 12 TRUE
hsa-mir-151 PRKCE 3 384 5.83E-02 2 TRUE
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Figure 10: Examples of prostate cancer gene-miRNA-SNP trios with significant regulatory differences
across genotypes. All trio interactions pFDR < 0.05.
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7 Supplementary Information
7.1 Source code
Source code for this analysis is available from https://github.com/gawilk/miRNA-SNP
7.2 SNP PCA plots
We applied PCA to SNP genotype data to test for population substructure. Although TCGA heavily samples
from European ancestry, there are other ancestry groups represented. Nevertheless, most of the samples
heavily cluster within the first two principal components, even in cancer types which have large sample
sizes of other or unknown ancestry, suggesting little population substructure in the cohort. PCA was applied
using the snpStats [1] package in R.
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Figure 11: PCA plot of Breast SNP genotype data. The entire cohort (left plot) and the main cluster zoomed
in (right plot) for the first two principal components. Sample groups appear to cluster together and exhibit
little population substructure.
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Figure 12: PCA plot of Liver SNP genotype data.
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Figure 13: PCA plot of Lung SNP genotype data.
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Figure 14: PCA plot of Prostate SNP genotype data.
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